Compare Gilead Sciences, Inc. (GILD) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Keysight Technologies Inc — how do they compare? Gilead Sciences, Inc. trades at $135.36 (market cap $163.51B), while Keysight Technologies Inc trades at $322.57 (market cap $55.15B). The key difference: Gilead Sciences, Inc. is far larger — about 3× Keysight Technologies Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals.
| GILD | KEYS | |
|---|---|---|
Market Cap | $163.51B | $55.15B |
Sector | Health | Technology |
52-Week High | $155.80 | $373.34 |
52-Week Low | $108.22 | $158.51 |
Enterprise Value | $178.05B | $55.50B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Keysight Technologies (KEYS) trades at $314.15, down 3.56% today, with a neutral technical outlook despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.87 exceeding expectations by 24%. Recent developments include partnerships with the European Space Agency and new product launches in cybersecurity testing and photonics design automation, positioning the company for growth in 5G and AI-driven markets.
Wall Street maintains strong bullish sentiment with 81% buy ratings and a $396.56 consensus price target, representing 26% upside potential. However, elevated valuation ratios (P/E 51.97, P/S 9.14) and recent cash flow volatility present risks. The company's expansion into high-growth technology sectors provides opportunity, but investors should monitor execution on projected 2026 revenue growth to $6.1B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
